Estelle M.N. Laurent, Da Kuang, Frederick P. Roth, Michel Salzet, Sylvie van der Werf, David E. Hill, Caroline Demeret, Dae-Kyum Kim, Oxana Pogoutse, Georgios A. Pavlopoulos, Anne-Claude Gingras, Michael A. Calderwood, Marc Vidal, Hala Abdouni, Patricia Cassonnet, Yves Jacob, Anastassia V. Komarova, Aditya Chawla, Patrick Aloy, Isabelle Fournier, Ashyad Rayhan, Pascal Falter-Braun, Jean-Pascal Gimeno, Ulrich Stelzl, Roujia Li, Etienne Coyaud, Jennifer J. Knapp, Dayag Sheykhkarimli, Marie Duhamel, Payman Samavarchi Tehrani, Yorgos Sofianatos, CASSONNET, Patricia, Protéomique, Réponse Inflammatoire, Spectrométrie de Masse (PRISM) - U 1192 (PRISM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institute for Fundamental Biomedical Research [Vari, Greece], Biomedical Sciences Research Centre Alexander Fleming [Vari, Greece] (BSRC), Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses (GMV-ARN (UMR_3569 / U-Pasteur_2)), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Lunenfeld-Tanenbaum Research Institute [Toronto, Canada], Dana-Farber Cancer Institute [Boston], Harvard Medical School [Boston] (HMS), Ludwig-Maximilians-Universität München (LMU), Barcelona Institute of Science and Technology (BIST), Karl-Franzens-Universität Graz, The operational costs of this project were supported by the Agence Nationale pour la Recherche (ANR) Flash COVID-19 funding scheme (DARWIN project). E.MN.L. was supported by Métropole Européenne de Lille (France). Y.S. was supported by the Operational Program Competitiveness, Entrepreneurship and Innovation, NSRF 2014-2020, Action code: MIS 5002562, co-financed by Greece and the European Union (European Regional Development Fund) and by the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 838018. GAP was supported by the Hellenic Foundation for Research and Innovation (H.F.R.I) under the 'First Call for H.F.R.I Research Projects to support Faculty members and Researchers and the procurement of high-cost research equipment grant' (grant 1855-BOLOGNA). FPR is supported by a Canadian Institutes of Health Research (CIHR) Foundation Grant and the Canada Excellence Research Chairs Program. A.-C.G. holds the Canada Research Chair (Tier 1) in Functional Proteomics. P.A. and P.F.B. were funded by the European Research Council’s Horizon 2020 Research and Innovation Action (Grant Agreement 101003633 - RiPCoN). E.C. was funded by I-Site Lille, Région Hauts-de-France and European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 843052., Université de Lille-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP), Karl-Franzens-Universität [Graz, Autriche], University of Graz, and ANR-20-COVI-0063,DARWIN,Identification des interactions entre protéines du SARS CoV-2 et les facteurs de la réponse immunitaire innée(2020)
The worldwide SARS-CoV-2 outbreak poses a serious challenge to human societies and economies. SARS-CoV-2 proteins orchestrate complex pathogenic mechanisms that underlie COVID-19 disease. Thus, understanding how viral polypeptides rewire host protein networks enables better-founded therapeutic research. In complement to existing proteomic studies, in this study we define the first proximal interaction network of SARS-CoV-2 proteins, at the whole proteome level in human cells. Applying a proximity-dependent biotinylation (BioID)-based approach greatly expanded the current knowledge by detecting interactions within poorly soluble compartments, transient, and/or of weak affinity in living cells. Our BioID study was complemented by a stringent filtering and uncovered 2,128 unique cellular targets (1,717 not previously associated with SARS-CoV-1 or 2 proteins) connected to the N- and C-ter BioID-tagged 28 SARS-CoV-2 proteins by a total of 5,415 (5,236 new) proximal interactions. In order to facilitate data exploitation, an innovative interactive 3D web interface was developed to allow customized analysis and exploration of the landscape of interactions (accessible at http://www.sars-cov-2-interactome.org/). Interestingly, 342 membrane proteins including interferon and interleukin pathways factors, were associated with specific viral proteins. We uncovered ORF7a and ORF7b protein proximal partners that could be related to anosmia and ageusia symptoms. Moreover, comparing proximal interactomes in basal and infection-mimicking conditions (poly(I:C) treatment) allowed us to detect novel links with major antiviral response pathway components, such as ORF9b with MAVS and ISG20; N with PKR and TARB2; NSP2 with RIG-I and STAT1; NSP16 with PARP9-DTX3L. Altogether, our study provides an unprecedented comprehensive resource for understanding how SARS-CoV-2 proteins orchestrate host proteome remodeling and innate immune response evasion, which can inform development of targeted therapeutic strategies.